Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The treatment of non-muscle invasive bladder cancer (NMIBC) is problematic given the variable
natural history of the disease. Although contemporary treatment options are limited, new
targets and new approaches are under investigation for preventing bladder cancer recurrence
and progression. Among those, COX-2 is a promising target since plays an important role in
urothelial carcinogenesis and iCOX-2 selective inhibitors, like celecoxib, effectively
inhibit tumor development and growth and enhances survival, in bladder cancer in vitro and in
vivo models.
Therefore, the investigators conducted a pilot study of celecoxib to prevent recurrence in
patients with intermediate risk NMIBC.
Phase:
Phase 2
Details
Lead Sponsor:
Azienda Ospedaliero-Universitaria Consorziale Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari